Financial Ratios Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
23.99 ^USD	+0.04%		+1.78%	+27.34%

Dec. 03	Pacira Biosciences reports inducement grants under Nasdaq Listing Rule	RE
Dec. 02	Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain	MT

61c701.xQlbW3AtkdZkjfei512Dd1hQuxpwGtBuBt0araISNjU.jWUpDRt8ybMv6L2SkzT5PG0XiU4daIEhUpVC6uBkWnGGaDUsCmTgsgn9ug

Published financial data: PACIRA BIOSCIENCES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	430M	542M	667M	675M	701M
Total Revenues	430M	542M	667M	675M	701M
Cost of Goods Sold, Total	177M	196M	274M	261M	252M
Gross Profit	253M	346M	393M	414M	449M
Selling General & Admin Expenses, Total	194M	199M	255M	269M	294M
Amortization of Goodwill and Intangible Assets - (IS)	7.87M	13.55M	57.29M	57.29M	57.29M
Other Operating Expenses, Total	201M	213M	312M	327M	351M
Operating Income	51.52M	133M	81.43M	87.32M	97.57M
Interest Expense, Total	-25.67M	-31.75M	-39.98M	-20.31M	-16.57M
Interest And Investment Income	4.63M	896K	4.54M	11.44M	19.69M
Net Interest Expenses	-21.04M	-30.85M	-35.43M	-8.86M	3.12M
Currency Exchange Gains (Loss)	-	-	-	-	-
Other Non Operating Income (Expenses)	1.23M	7K	-1.2M	-186K	-373K
EBT, Excl. Unusual Items	31.71M	102M	44.8M	78.28M	100M
Restructuring Charges	188K	-	-	-1.11M	-8.53M
Merger & Related Restructuring Charges	-150K	-40.9M	-11.24M	-1.96M	-1.46M
Impairment of Goodwill	-	-	-	-	-163M
Gain (Loss) On Sale Of Investments	1.62M	-2.67M	-10.09M	-	-
Asset Writedown	-	-	-36.63M	-	-
Legal Settlements	-	-	-	-	-
Other Unusual Items	-13.28M	-2.01M	26.48M	-13.5M	9.81M
EBT, Incl. Unusual Items	20.09M	56.4M	13.3M	61.7M	-63.11M
Income Tax Expense	-125M	14.42M	-2.61M	19.75M	36.45M
Earnings From Continuing Operations	146M	41.98M	15.91M	41.96M	-99.56M
Net Income to Company	146M	41.98M	15.91M	41.96M	-99.56M
Net Income - (IS)	146M	41.98M	15.91M	41.96M	-99.56M
Net Income to Common Incl Extra Items	146M	41.98M	15.91M	41.96M	-99.56M
Net Income to Common Excl. Extra Items	146M	41.98M	15.91M	41.96M	-99.56M
Per Share Items
Net EPS - Basic	3.41	0.95	0.35	0.91	-2.15
Basic EPS - Continuing Operations	3.41	0.95	0.35	0.91	-2.15
Basic Weighted Average Shares Outstanding	42.67M	44.26M	45.52M	46.22M	46.24M
Net EPS - Diluted	3.33	0.92	0.34	0.89	-2.15
Diluted EPS - Continuing Operations	3.33	0.92	0.34	0.89	-2.15
Diluted Weighted Average Shares Outstanding	43.68M	45.63M	46.54M	51.98M	46.24M
Normalized Basic EPS	0.46	1.44	0.62	1.06	1.36
Normalized Diluted EPS	0.45	1.4	0.6	0.94	1.36
Supplemental Items
EBITDA	71.42M	161M	162M	163M	176M
EBITA	59.38M	146M	139M	145M	155M
EBIT	51.52M	133M	81.43M	87.32M	97.57M
EBITDAR	83.58M	175M	178M	179M	192M
Total Revenues (As Reported)	430M	542M	667M	675M	701M
Effective Tax Rate - (Ratio)	-624.39	25.57	-19.6	32	-57.77
Current Domestic Taxes	1.18M	3.53M	5.31M	4.13M	15.82M
Current Foreign Taxes	-	19K	29K	1K	11K
Total Current Taxes	1.18M	3.55M	5.34M	4.13M	15.83M
Deferred Domestic Taxes	-127M	10.87M	-7.94M	15.62M	20.62M
Total Deferred Taxes	-127M	10.87M	-7.94M	15.62M	20.62M
Normalized Net Income	19.82M	63.74M	28M	48.92M	62.7M
Interest Capitalized	2.4M	3.9M	4.1M	3.5M	2.1M
Interest on Long-Term Debt	28.06M	35.66M	44.09M	23.83M	18.67M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	59.42M	55.54M	111M	76.26M	81.58M
Net Rental Expense, Total	12.15M	13.7M	15.68M	15.64M	15.46M
Imputed Operating Lease Interest Expense	6.11M	4.68M	5.85M	4.41M	3.77M
Imputed Operating Lease Depreciation	6.04M	9.02M	9.84M	11.22M	11.69M
Stock-Based Comp., COGS (Total)	10.8M	11.36M	12.56M	14.23M	12.71M
Stock-Based Comp., SG&A Exp. (Total)	29.12M	30.89M	35.53M	33.66M	34.86M
Stock-Based Comp., Other (Total)	-	-	-	-	3.6M
Total Stock-Based Compensation	39.92M	42.25M	48.09M	47.9M	51.17M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	99.96M	586M	104M	153M	277M
Short Term Investments	422M	70.83M	185M	125M	208M
Total Cash And Short Term Investments	522M	656M	289M	279M	485M
Accounts Receivable, Total	53.05M	96.32M	98.4M	106M	113M
Other Receivables	1.6M	100K	800K	400K	500K
Total Receivables	54.65M	96.42M	99.2M	106M	114M
Inventory	64.65M	98.55M	96.06M	104M	125M
Prepaid Expenses	10.66M	14.67M	14.42M	20.4M	20.43M
Other Current Assets, Total	-	-	-	700K	1M
Total Current Assets	652M	866M	498M	510M	745M
Gross Property Plant And Equipment	290M	350M	372M	370M	349M
Accumulated Depreciation	-78.36M	-85.24M	-117M	-135M	-133M
Net Property Plant And Equipment	211M	265M	254M	235M	216M
Long-term Investments	107M	21.99M	64.38M	32.26M	29.45M
Goodwill	99.55M	145M	163M	163M	-
Other Intangibles, Total	96.52M	624M	541M	483M	426M
Deferred Tax Assets Long-Term	106M	153M	160M	144M	130M
Other Long-Term Assets, Total	2.42M	-	-	6.2M	6.2M
Total Assets	1.27B	2.08B	1.68B	1.57B	1.55B
Liabilities
Accounts Payable, Total	10.43M	10.54M	15.22M	15.7M	19.13M
Accrued Expenses, Total	68.78M	119M	82.49M	55.72M	69.52M
Short-term Borrowings	-	-	-	-	-
Current Portion of Long-Term Debt	150M	375M	33.65M	8.64M	202M
Current Portion of Leases	7.42M	7.89M	9.12M	8.8M	8.89M
Current Income Taxes Payable	114K	429K	-	-	-
Unearned Revenue Current, Total	-	-	-	-	-
Other Current Liabilities	16.93M	8.95M	7.3M	8.53M	10.61M
Total Current Liabilities	253M	521M	148M	97.38M	310M
Long-Term Debt	313M	675M	656M	514M	384M
Long-Term Leases	71.02M	71.73M	64.8M	54.81M	44.64M
Unearned Revenue Non Current	-	10.12M	-	-	-
Other Non Current Liabilities	17.44M	67.44M	37.79M	38.27M	37.06M
Total Liabilities	655M	1.34B	906M	704M	775M
Common Stock, Total	44K	45K	46K	46K	47K
Additional Paid In Capital	873M	942M	924M	977M	1.01B
Retained Earnings	-254M	-212M	-149M	-107M	-206M
Treasury Stock	-	-	-	-	-25.12M
Comprehensive Income and Other	318K	167K	-380K	247K	343K
Total Common Equity	620M	730M	775M	870M	778M
Total Equity	620M	730M	775M	870M	778M
Total Liabilities And Equity	1.27B	2.08B	1.68B	1.57B	1.55B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	43.86M	44.85M	45.95M	46.5M	46.28M
ECS Total Common Shares Outstanding	43.64M	44.73M	45.93M	46.48M	46.24M
Book Value / Share	14.2	16.33	16.87	18.72	16.83
Tangible Book Value	424M	-38.74M	71.22M	224M	352M
Tangible Book Value Per Share	9.71	-0.87	1.55	4.81	7.62
Total Debt	541M	1.13B	763M	586M	639M
Net Debt	19.47M	472M	475M	307M	154M
Debt Equivalent Oper. Leases	97.21M	110M	125M	125M	124M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	26.89M	36.34M	39.81M	54.1M	50.8M
Inventories - Work In Process, Total	16.27M	35.18M	28.85M	31.22M	27.38M
Inventories - Finished Goods, Total	21.5M	27.03M	27.4M	19.04M	47.1M
Machinery, Total	89.52M	133M	136M	142M	186M
Full Time Employees	624	697	715	711	788
Part Time Employees	-	-	-	1	2
Accumulated Allowance for Doubtful Accounts (Supple)	-	-	-	-	400K

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	146M	41.98M	15.91M	41.96M	-99.56M
Depreciation & Amortization - CF	12.04M	15M	23.71M	18.29M	21.5M
Amortization of Goodwill and Intangible Assets - (CF)	7.87M	13.55M	57.29M	57.29M	57.29M
Depreciation & Amortization, Total	19.91M	28.55M	81M	75.57M	78.78M
Amortization of Deferred Charges, Total - (CF)	20.41M	25.91M	7.21M	3.75M	3.22M
(Gain) Loss From Sale Of Asset	22K	-10K	193K	-	-
(Gain) Loss on Sale of Investments - (CF)	-1.62M	2.67M	10.09M	-	-
Asset Writedown & Restructuring Costs	-	-	36.63M	-	163M
Stock-Based Compensation (CF)	39.92M	42.25M	48.09M	47.9M	51.17M
Other Operating Activities, Total	-113M	9.88M	-37.42M	31.25M	11.05M
Change In Accounts Receivable	-5.52M	-10.43M	-2.08M	-7.16M	-7.75M
Change In Inventories	-6.35M	-4.47M	2.49M	-8.29M	-20.93M
Change In Accounts Payable	-3.31M	-10.26M	6.27M	916K	3.08M
Change in Unearned Revenues	-	125K	-	-	-
Change in Other Net Operating Assets	-18.61M	-471K	-23.11M	-31.24M	7.07M
Cash from Operations	77.03M	126M	145M	155M	189M
Capital Expenditure	-37.8M	-45.87M	-30.08M	-15.16M	-10.64M
Cash Acquisitions	-	-424M	-32M	-	-
Investment in Marketable and Equity Securities, Total	-240M	449M	-163M	92.7M	-72.64M
Cash from Investing	-278M	-20.79M	-225M	77.54M	-83.28M
Long-Term Debt Issued, Total	315M	364M	-	150M	288M
Total Debt Issued	315M	364M	-	150M	288M
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-177M	-	-428M	-330M	-211M
Total Debt Repaid	-177M	-	-428M	-330M	-211M
Issuance of Common Stock	136M	26.66M	27.34M	4.75M	2.3M
Repurchase of Common Stock	-33.09M	-	-	-106K	-25.49M
Other Financing Activities, Total	-18.08M	-9.71M	-1.18M	-6.91M	-36.06M
Cash from Financing	222M	381M	-402M	-183M	17.36M
Net Change in Cash	21.73M	486M	-481M	49.16M	123M
Supplemental Items
Cash Interest Paid	7.2M	7M	33.3M	27.64M	15.42M
Cash Income Tax Paid (Refund)	2.42M	3.22M	7.4M	4.37M	11.02M
Levered Free Cash Flow	38.75M	76.61M	98.56M	107M	163M
Unlevered Free Cash Flow	34.39M	70.54M	116M	116M	171M
Change In Net Working Capital	19.84M	37.41M	33.57M	46.79M	9.79M
Net Debt Issued / Repaid	138M	364M	-428M	-181M	76.62M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	3.06	4.96	2.71	3.35	3.9
Return on Total Capital	3.45	5.5	3	3.64	4.24
Return On Equity %	29.86	6.22	2.11	5.1	-12.08
Return on Common Equity	29.86	6.22	2.11	5.1	-12.08
Margin Analysis
Gross Profit Margin %	58.86	63.84	58.97	61.34	64.05
SG&A Margin	45.04	36.81	38.17	39.92	41.96
EBITDA Margin %	16.62	29.8	24.36	24.13	25.16
EBITA Margin %	13.82	27.03	20.8	21.42	22.09
EBIT Margin %	11.99	24.53	12.21	12.94	13.92
Income From Continuing Operations Margin %	33.87	7.75	2.39	6.22	-14.2
Net Income Margin %	33.87	7.75	2.39	6.22	-14.2
Net Avail. For Common Margin %	33.87	7.75	2.39	6.22	-14.2
Normalized Net Income Margin	4.61	11.77	4.2	7.25	8.94
Levered Free Cash Flow Margin	9.02	14.15	14.78	15.87	23.31
Unlevered Free Cash Flow Margin	8	13.03	17.45	17.2	24.33
Asset Turnover
Asset Turnover	0.41	0.32	0.36	0.41	0.45
Fixed Assets Turnover	2.43	2.28	2.57	2.76	3.11
Receivables Turnover (Average Receivables)	8.54	7.25	6.85	6.62	6.41
Inventory Turnover (Average Inventory)	2.88	2.4	2.81	2.6	2.19
Short Term Liquidity
Current Ratio	2.57	1.66	3.37	5.24	2.4
Quick Ratio	2.27	1.44	2.62	3.95	1.93
Operating Cash Flow to Current Liabilities	0.3	0.24	0.98	1.59	0.61
Days Sales Outstanding (Average Receivables)	42.84	50.34	53.29	55.14	57.14
Days Outstanding Inventory (Average Inventory)	127.29	152.11	129.82	140.18	166.76
Average Days Payable Outstanding	23.22	16.66	17.34	20.96	23.35
Cash Conversion Cycle (Average Days)	146.92	185.79	165.76	174.36	200.54
Long Term Solvency
Total Debt/Equity	87.32	154.55	98.5	67.35	82.08
Total Debt / Total Capital	46.62	60.72	49.62	40.25	45.08
LT Debt/Equity	61.98	102.17	92.98	65.35	55.01
Long-Term Debt / Total Capital	33.08	40.14	46.84	39.05	30.21
Total Liabilities / Total Assets	51.38	64.81	53.9	44.73	49.9
EBIT / Interest Expense	2.01	4.18	2.04	4.3	5.89
EBITDA / Interest Expense	3.26	5.51	4.46	8.79	11.58
(EBITDA - Capex) / Interest Expense	1.78	4.07	3.7	8.05	10.94
Total Debt / EBITDA	6.47	6.45	4.29	3.28	3.33
Net Debt / EBITDA	0.23	2.7	2.67	1.72	0.8
Total Debt / (EBITDA - Capex)	11.82	8.74	5.16	3.59	3.53
Net Debt / (EBITDA - Capex)	0.43	3.66	3.21	1.88	0.85
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	2.05	26.04	23.14	1.22	3.85
Gross Profit, 1 Yr. Growth %	4.42	36.71	13.74	8.18	8.43
EBITDA, 1 Yr. Growth %	29.19	132.8	0.65	7.22	8.26
EBITA, 1 Yr. Growth %	43.39	155.56	-5.24	12.79	7.09
EBIT, 1 Yr. Growth %	44.26	168.81	-38.7	23.12	11.74
Earnings From Cont. Operations, 1 Yr. Growth %	-1.42K	-71.15	-62.1	163.72	-337.3
Net Income, 1 Yr. Growth %	-1.42K	-71.15	-62.1	163.72	-337.3
Normalized Net Income, 1 Yr. Growth %	57.11	244.46	-56.08	128.84	28.16
Diluted EPS Before Extra, 1 Yr. Growth %	-1.33K	-72.37	-63.04	160.68	-342.91
Accounts Receivable, 1 Yr. Growth %	11.61	81.57	2.16	7.28	7.34
Inventory, 1 Yr. Growth %	10.9	52.44	-2.52	8.63	20.06
Net Property, Plant and Equip., 1 Yr. Growth %	47.88	25.4	-3.94	-7.64	-7.9
Total Assets, 1 Yr. Growth %	53.36	62.83	-18.99	-6.35	-1.33
Tangible Book Value, 1 Yr. Growth %	180.52	-109.14	-283.87	213.99	57.57
Common Equity, 1 Yr. Growth %	74.59	17.87	6.11	12.27	-10.55
Cash From Operations, 1 Yr. Growth %	9.23	63.2	15.56	6.45	22.46
Capital Expenditures, 1 Yr. Growth %	272.09	21.34	-34.43	-49.59	-29.85
Levered Free Cash Flow, 1 Yr. Growth %	-55.14	104.61	28.66	16.46	52.48
Unlevered Free Cash Flow, 1 Yr. Growth %	-59.88	113.28	64.92	5.75	46.88
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	12.87	13.41	24.58	11.64	2.53
Gross Profit, 2 Yr. CAGR %	13.96	19.48	24.7	9.44	8.31
EBITDA, 2 Yr. CAGR %	52.78	70.85	50.8	17.26	7.74
EBITA, 2 Yr. CAGR %	84.55	88.01	52.84	18.22	9.9
EBIT, 2 Yr. CAGR %	71.68	92.87	25.72	-1.46	17.29
Earnings From Cont. Operations, 2 Yr. CAGR %	1.66K	95.21	-66.94	-0.03	150.16
Net Income, 2 Yr. CAGR %	1.66K	95.21	-66.94	-0.03	150.16
Normalized Net Income, 2 Yr. CAGR %	298.87	124.8	18.86	15.18	71.26
Diluted EPS Before Extra, 2 Yr. CAGR %	1.6K	84.59	-68.05	-1.85	151.63
Accounts Receivable, 2 Yr. CAGR %	18.15	42.35	36.2	4.69	7.31
Inventory, 2 Yr. CAGR %	15.37	30.02	21.9	2.9	14.2
Net Property, Plant and Equip., 2 Yr. CAGR %	39.4	36.17	9.75	-5.81	-7.77
Total Assets, 2 Yr. CAGR %	35.97	58.03	14.85	-12.9	-3.87
Tangible Book Value, 2 Yr. CAGR %	27.84	-49.35	-59	140.28	122.43
Common Equity, 2 Yr. CAGR %	38.89	43.45	11.83	9.15	0.22
Cash From Operations, 2 Yr. CAGR %	25.55	33.52	37.33	10.91	14.18
Capital Expenditures, 2 Yr. CAGR %	61.38	112.48	-10.8	-42.51	-40.53
Levered Free Cash Flow, 2 Yr. CAGR %	10.66	-5.84	59.48	46.7	33.26
Unlevered Free Cash Flow, 2 Yr. CAGR %	5.43	-9.28	83.94	62.94	24.63
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	14.44	17.1	16.56	16.25	8.98
Gross Profit, 3 Yr. CAGR %	21.21	21.09	17.53	17.86	9.1
EBITDA, 3 Yr. CAGR %	131.06	74.07	43.22	31.63	14.18
EBITA, 3 Yr. CAGR %	44.64	103.25	49.62	34.54	14.38
EBIT, 3 Yr. CAGR %	38.26	96.61	31.62	19.23	2.76
Earnings From Cont. Operations, 3 Yr. CAGR %	50.59	346.69	13.03	-33.94	33.36
Net Income, 3 Yr. CAGR %	50.59	346.69	13.03	-33.94	33.36
Normalized Net Income, 3 Yr. CAGR %	-1.61	271.26	30.45	35.15	19.35
Diluted EPS Before Extra, 3 Yr. CAGR %	45.98	330.74	7.99	-35.68	32.76
Accounts Receivable, 3 Yr. CAGR %	18.77	36.35	27.45	25.78	5.56
Inventory, 3 Yr. CAGR %	16.01	26.6	18.12	17.3	8.33
Net Property, Plant and Equip., 3 Yr. CAGR %	25.42	34.57	21.22	3.62	-6.51
Total Assets, 3 Yr. CAGR %	26.58	44.39	26.47	7.3	-9.2
Tangible Book Value, 3 Yr. CAGR %	23.61	-46.93	-22.16	-19.18	108.75
Common Equity, 3 Yr. CAGR %	30.4	31.5	29.73	11.98	2.14
Cash From Operations, 3 Yr. CAGR %	63.01	37.02	27.24	26.15	14.64
Capital Expenditures, 3 Yr. CAGR %	25.19	46.75	43.59	-26.25	-38.56
Levered Free Cash Flow, 3 Yr. CAGR %	33.84	34.27	4.49	40.35	48.6
Unlevered Free Cash Flow, 3 Yr. CAGR %	30.04	31.63	10.72	50.01	57.4
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	11.53	14.4	18.4	14.88	10.73
Gross Profit, 5 Yr. CAGR %	11.24	23.45	22.59	16.28	13.14
EBITDA, 5 Yr. CAGR %	27.99	53.02	94.8	39.71	26.11
EBITA, 5 Yr. CAGR %	43.91	35.51	47.87	52.67	30.19
EBIT, 5 Yr. CAGR %	40.36	32.91	33.1	37.95	22.27
Earnings From Cont. Operations, 5 Yr. CAGR %	139.26	2.04	-17.88	145.44	55.31
Net Income, 5 Yr. CAGR %	139.26	2.04	-17.88	145.44	55.31
Normalized Net Income, 5 Yr. CAGR %	70.95	21.93	6.12	108.36	37.81
Diluted EPS Before Extra, 5 Yr. CAGR %	142.15	-2.04	-20.5	138.39	51.47
Accounts Receivable, 5 Yr. CAGR %	15.46	26.33	25.46	22.67	18.97
Inventory, 5 Yr. CAGR %	0.96	25.8	18.33	16.53	16.53
Net Property, Plant and Equip., 5 Yr. CAGR %	18.51	21.26	18.9	16.67	8.67
Total Assets, 5 Yr. CAGR %	26.87	39.6	21.75	17.96	13.33
Tangible Book Value, 5 Yr. CAGR %	17.71	-25.8	-20.5	-2.91	18.47
Common Equity, 5 Yr. CAGR %	23.19	27.24	22.63	22.05	17
Cash From Operations, 5 Yr. CAGR %	22.42	30.31	52.2	25.91	21.85
Capital Expenditures, 5 Yr. CAGR %	-1.27	13.17	9.32	0.88	0.92
Levered Free Cash Flow, 5 Yr. CAGR %	18.29	28.56	43.56	27.62	13.59
Unlevered Free Cash Flow, 5 Yr. CAGR %	15.71	26.8	49.39	30.28	14.75